News Releases

Year

01 Jun '21

Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting

Baseline demographic and biomarker data reinforce appropriate patient population enrolled ahead of top-line data expected in fourth quarter 2021 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 1, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease

PDF Version

26 May '21

Cortexyme to Present at Investor Conferences in June 2021

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris

PDF Version

10 May '21

Cortexyme Provides Business Update and Reports First Quarter 2021 Results

Top-line data from 643-subject Alzheimer’s disease pivotal GAIN Trial expected in fourth quarter 2021 Top-line data from 233-subject periodontal disease Phase 2 REPAIR sub-study of the GAIN Trial expected in fourth quarter 2021 COR588 on track to initiate first-in-human studies in third quarter

PDF Version

04 May '21

Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 4, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Chris

PDF Version

25 Mar '21

Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 25, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Casey

PDF Version

10 Mar '21

Cortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021

-- Presentation to be webcast on Cortexyme’s website -- SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 10, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today announced Chris Lowe , the company’s chief

PDF Version

08 Mar '21

Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer’s Disease Data Presentation

-- Partnership with Parkinson Study Group Advisory Panel to collaborate on Parkinson’s Disease Program -- -- Presentation at AD/PD™ 2021 Underscores Relevance of Cortexyme’s Approach -- SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 8, 2021-- Cortexyme, Inc.

PDF Version

15 Feb '21

Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer’s Disease

- Double-blind phase of GAIN Trial to continue as planned, with top-line data expected Q4 2021 - Open-Label Extension of atuzaginstat to stop dosing and enrollment SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 15, 2021-- Cortexyme, Inc. (NASDAQ: CRTX), a clinical-stage biopharmaceutical

PDF Version

10 Feb '21

Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion

— Chris Lowe Promoted to Chief Operating Officer and Chief Financial Officer — Ted Monohon Promoted to Chief Accounting Officer —Drew Sukovich, Ph.D., RAC, Joins as Vice President, Regulatory and Quality SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 10, 2021-- Cortexyme, Inc.

PDF Version

26 Jan '21

Cortexyme Announces Pipeline Update and Anticipated 2021 Milestones

— Based upon successful completion of the GAIN Trial’s interim analysis, pipeline expansion announced for 2021 — Atuzaginstat to be studied in the PEAK trial, a new Phase 2 study for Parkinson’s disease — COR588, a novel lysine gingipain inhibitor, on track to enter the clinic in Q3 2021 — Top-line

PDF Version